At this very moment, pharmaceutical companies and biotech startups from San Francisco and Boston to Tianjin, Tokyo and Galilee, are staging a multi-front battle against the novel coronavirus akin to the sea, land and air assault conducted by the allies against Nazi Germany on D-Day during World War II.
Last September, Gallup released an opinion poll that surveyed Americans’ views of U.S. businesses, ranking 25 different sectors from very positive to very negative: The pharmaceutical industry came in dead last, lower than at any time since Gallup started the poll in 2001.
Today, at least 267 different COVID-19 remedies are being developed, according to an analysis by Umer Raffat, a senior managing director of investment bank Evercore ISI, with more experimental treatments being added almost daily.
Six categories of 50 different drugs, vaccines and remedies now being developed to combat the coronavirus pandemic:
- Anti-inflammatory – therapeutics that target the immune system and prevent the virus from causing lung injury.
- Antibodies + Immunomodulators- a therapeutics approach that makes proteins to help the immune system neutralize the virus.
- Plasma Immunoglobulins – antibody-containing blood plasma from recovered Covid-19 patients.
- RNAI – therapeutics that use a biological process to intefere with the virus.
- Antivirals – drugs designed to attack and treat SARS-CoV-2 infection.
- Vaccines – drugs designed to foster immunity to Covid-19.
Forbes’ article provides a good overview and more information on the afore mentioned treatments in development.
blog